Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TXN | P10599 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4685300 | 0.86 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2TXNTXNRD1TAAR1 | |
| SCHEMBL4685296 | 0.84 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2TXNTXNRD1TAAR1 | |
| SCHEMBL2947883 | 0.76 | — | — | |
| SCHEMBL261678 | 0.75 | ALDH1A1 (0.40) | ALDH1A1SMN1; SMN2TAAR1NISCH | |
| SCHEMBL9013456 | 0.71 | TAAR1 (0.33) | TAAR1NISCH | |
| SCHEMBL3193203 | 0.71 | — | — | |
| SCHEMBL22024413 | 0.71 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2NISCH | |
| SCHEMBL12854154 | 0.71 | — | — | |
| SCHEMBL17007042 | 0.69 | SLC6A2 (0.35) | ALDH1A1 | |
| SCHEMBL4685982 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | Technische Universität Berlin (DE) | 2015-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | ALDH1A1 3311/4885SMN1; SMN2 3567/4885TXN 1946/4885 |
| US-20150376120-A1 | ALBICIDIN DERIVATIVES, THEIR USE AND SYNTHESIS | MB, ALB, BCAT2 | ALDH1A1 2409/4885SMN1; SMN2 1226/4885TXN 1238/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | ALDH1A1 3311/4885SMN1; SMN2 3567/4885TXN 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.